Quantcast
Last updated on April 20, 2014 at 8:28 EDT

Beneficial Collaborations, FDA Authorized Technologies and Divestitures Promoting Quality Healthcare – Research Report on Agilent, Life Technologies, C. R. Bard, Quest Diagnostics, and Alere

July 4, 2013

Editor Note: For more information about this release, please scroll to bottom.

NEW YORK, July 4, 2013 /PRNewswire/ –

Today, Wall Street Reports announced new research reports highlighting Agilent
Technologies Inc. (NYSE: A), Life Technologies Corporation (NASDAQ: LIFE), C. R. Bard,
Inc. (NYSE: BCR), Quest Diagnostics Inc. (NYSE: DGX), and Alere Inc. (NYSE: ALR). Today’s
readers may access these reports free of charge – including full price targets, industry
analysis and analyst ratings – via the links below.

Agilent Technologies Inc. Research Report

On June 25, 2013, Agilent Technologies Inc. (Agilent) introduced the U5340A FPGA
development kit for high speed digitizers. The kit, which is powered by a custom Mentor
Graphics design engine, enables customers to deploy advanced real-time signal processing
into the FPGAs on board Agilent high-speed digitizers. According to Agilent, the kit also
ensures that the digitizers deliver high multi-gigasample-per-second performance. “Our
close partnership with Mentor Graphics enabled us to create today’s most powerful FPGA
development kit for high-speed digitizers,” said Didier Lavanchy, Operation Manager for
Agilent’s High-Speed Digitizers Group. “We have used the kit to design firmware options
currently available in our products, and beta customers have successfully implemented a
variety of algorithms. For them and us, the U5340A has significantly reduced development
time and, for the first time, made possible multi-gigasample-per-second real-time
processing.” The Full Research Report on Agilent Technologies Inc. – including full
detailed breakdown, analyst ratings and price targets – is available to download free of
charge at: [http://www.wsreports.com/r/full_research_report/075f_A]

Life Technologies Corporation Research Report

On June 26, 2013, Life Technologies Corp. (Life Technologies) announced that its
Applied Biosystems 7500 Fast Dx Real-Time PCR instrument is suitable for use with the CDC
Novel Coronavirus 2012 Real-time RT-PCR Assay, which has received Emergency Use
Authorization for detection in patient specimens of the novel Middle East Respiratory
Syndrome Coronavirus (MERS-CoV). To ensure proper treatment against the growing threat
from MERS-CoV, Life Technologies stated that it is increasing production of its reagents
and shipping them to labs around the world. “We are working continually with our partners
to improve capabilities, particularly tests that work more quickly and simply on more
people,” said Mark Stevenson, President and Chief Operating Officer at Life Technologies.
“Our technology aids public health labs around the globe to identify threats and develop
rapid detection kits.” The Company informed that the test has been authorized by FDA under
an Emergency Use Authorization for use by qualified laboratories, however the CDC Novel
Coronavirus 2012 Assay has neither been FDA cleared nor approved. The Full Research Report
on Life Technologies Corporation – including full detailed breakdown, analyst ratings and
price targets – is available to download free of charge at: [

http://www.wsreports.com/r/full_research_report/d9de_LIFE]

C. R. Bard, Inc. Research Report

On June 28, 2013, C. R. Bard, Inc. (C. R. Bard) announced that it has entered into an
agreement to sell certain assets of its Electrophysiology (EP) division to Boston
Scientific Corporation for $275 million in cash. Timothy M. Ring, Chairman and Chief
Executive Officer, C. R. Bard, commented, “This divestiture is consistent with our
strategic plan, which is designed to position our portfolio for accelerated sales growth
over time. By exiting the EP business, we believe we can better direct management’s
attention and our capital resources toward pursuing opportunities where we believe we can
achieve sustainable long-term leadership positions and provide attractive growth and
returns to shareholders.” The Company anticipates this transaction to be approximately
$0.05 dilutive to its 2013 adjusted EPS. The Full Research Report on C. R. Bard, Inc. -
including full detailed breakdown, analyst ratings and price targets – is available to
download free of charge at: [http://www.wsreports.com/r/full_research_report/1010_BCR]

Quest Diagnostics Inc. Research Report

On June 26, 2013, Quest Diagnostics Inc. (Quest Diagnostics) announced an agreement
with AT&T to provide the Quest Diagnostics Care360 Solution Suite, including the Care360
electronic health record (EHR) and eprescribing and laboratory order/results services,
through AT&T Healthcare Community Online. As per the agreement, AT&T will offer, promote
and resell the Care360 Solution Suite through AT&T Healthcare Community Online “Our
relationship with AT&T is an example of how Quest Diagnostics is increasingly
collaborating with top companies to develop new solutions for serving the complex needs of
healthcare providers,” said Philip S. Present II, Vice President and General Manager of
Quest Diagnostics’ Healthcare Information Technology Service Line. “Through this
agreement, Quest will extend the availability of its Care360 Solution to a far larger
number of large physician practices, hospitals and integrated delivery networks, including
ACOs. AT&T, in turn, will benefit from being able to offer to its AT&T Healthcare
Community Online customers a highly comprehensive and flexible online EHR solution that
meets Meaningful Use criteria.” The Full Research Report on Quest Diagnostics Inc. -
including full detailed breakdown, analyst ratings and price targets – is available to
download free of charge at: [http://www.wsreports.com/r/full_research_report/0cb6_DGX]

Alere Inc. Research Report

On June 27, 2013, Alere Inc. (Alere) announced that it has partnered with various
Health Departments and Nonprofit Organizations to sponsor HIV testing events across the US
for the National HIV Testing Day (NHTD), which was observed on the same day. NHTD is an
annual observance that promotes testing as an important strategy to detect, treat and
prevent HIV infection. The campaign was meant to encourage people of all ages to “Take the
Test. Take Control.” According to the Centers of Disease Control and Prevention (CDC), in
2010, of all Americans infected with HIV, approximately 18% had not been diagnosed with
the infection. To support the cause, Alere donated free test kits and made local grants to
help raise awareness about HIV testing and encourage people to get tested for the virus.
The Full Research Report on Alere Inc. – including full detailed breakdown, analyst
ratings and price targets – is available to download free of charge at: [

http://www.wsreports.com/r/full_research_report/50a5_ALR]

—-

EDITOR NOTES:

        1) This is not company news. We are an independent source and our views do
          not reflect the companies mentioned.
        2) Information in this release is fact checked and produced on a best efforts
          basis and reviewed by a CFA. However, we are only human and are prone to make
          mistakes. If you notice any errors or omissions, please notify us below.
        3) This information is submitted as a net-positive to companies mentioned, to
          increase awareness for mentioned companies to our subscriber base and the investing
          public.
        4) If you wish to have your company covered in more detail by our team, or wish
          to learn more about our services, please contact us at
          pubco@EquityNewsNetwork.com.
        5) For any urgent concerns or inquiries, please contact us at
          compliance@EquityNewsNetwork.com.
        6) Are you a public company? Would you like to see similar coverage on your
          company? Send us a full investors' package to research@EquityNewsNetwork.com for
          consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document,
article or report is prepared and authored by Equity News Network. An outsourced research
services provider has, through Chartered Financial Analysts, only reviewed the information
provided by Equity News Network in this article or report according to the Procedures
outlined by Equity News Network. Equity News Network is not entitled to veto or interfere
in the application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or
completeness or fitness for a purpose (investment or otherwise), of the information
provided in this document. This information is not to be construed as personal financial
advice. Readers are encouraged to consult their personal financial advisor before making
any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the
time of printing of this document or any error, mistake or shortcoming. No liability is
accepted by Equity News Network whatsoever for any direct, indirect or consequential loss
arising from the use of this document. Equity News Network expressly disclaims any
fiduciary responsibility or liability for any consequences, financial or otherwise arising
from any reliance placed on the information in this document. Equity News Network does not
(1) guarantee the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The included
information is subject to change without notice.

SOURCE Wall Street Reports


Source: PR Newswire